ATE435219T1 - Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase - Google Patents

Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Info

Publication number
ATE435219T1
ATE435219T1 AT03722769T AT03722769T ATE435219T1 AT E435219 T1 ATE435219 T1 AT E435219T1 AT 03722769 T AT03722769 T AT 03722769T AT 03722769 T AT03722769 T AT 03722769T AT E435219 T1 ATE435219 T1 AT E435219T1
Authority
AT
Austria
Prior art keywords
sulfamides
heteroaryl substituted
gamma secretase
substituted spirocyclic
inhibit gamma
Prior art date
Application number
AT03722769T
Other languages
English (en)
Inventor
Ian James Collins
Laura Catherine Cooper
Timothy Harrison
Linda Elizabeth Keown
Andrew Madin
Mark Peter Ridgill
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209996A external-priority patent/GB0209996D0/en
Priority claimed from GB0223873A external-priority patent/GB0223873D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE435219T1 publication Critical patent/ATE435219T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03722769T 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase ATE435219T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0209996A GB0209996D0 (en) 2002-05-01 2002-05-01 Therapeutic agents
GB0223873A GB0223873D0 (en) 2002-10-14 2002-10-14 Therapeutic agents
US42460802P 2002-11-07 2002-11-07
PCT/GB2003/001763 WO2003093252A1 (en) 2002-05-01 2003-04-24 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase

Publications (1)

Publication Number Publication Date
ATE435219T1 true ATE435219T1 (de) 2009-07-15

Family

ID=29407321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03722769T ATE435219T1 (de) 2002-05-01 2003-04-24 Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase

Country Status (7)

Country Link
US (3) US7041689B2 (de)
EP (1) EP1503998B1 (de)
AT (1) ATE435219T1 (de)
AU (1) AU2003229932B2 (de)
CA (1) CA2484159C (de)
DE (1) DE60328182D1 (de)
WO (1) WO2003093252A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248397T3 (es) * 2000-11-02 2006-03-16 MERCK SHARP & DOHME LTD. Sulfamidas como inhibidores de la gamma-secretasa.
US7399775B2 (en) 2001-12-27 2008-07-15 Daiichi Pharmaceutical Co., Ltd. β-amyloid protein production/secretion inhibitor
GB0209995D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
DE60328182D1 (de) * 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0225475D0 (en) * 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
RU2336270C2 (ru) 2003-06-30 2008-10-20 Дайити Фармасьютикал Ко., Лтд. Гетероциклические метилсульфоновые производные
WO2005030731A1 (en) * 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
US8242103B2 (en) 2005-05-19 2012-08-14 Merck Sharp & Dohme Limited Sulphamides for treatment of cancer
US20080058316A1 (en) 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
EP2094836B1 (de) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Erzeugung von innerohrzellen
EP2121633A2 (de) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010000372A2 (en) * 2008-06-09 2010-01-07 Ludwig-Maximilians-Universität München New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション p53活性を増大する置換ピペリジン及びその使用
AU2010341229A1 (en) * 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
EP3970725B1 (de) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary Ein gamma-sekretase-inhibitor zur behandlung von gehörverlust
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituierte imidazopyridine als hdm2 inhibitoren
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CA3013038A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
WO2017200762A2 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
CN110337291A (zh) 2016-12-16 2019-10-15 帕珀莱恩医疗公司 治疗耳蜗突触病变的方法
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP4076459B1 (de) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
KR20250053961A (ko) 2022-09-02 2025-04-22 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 토포이소머라제-1 억제제 제약 조성물 및 그의 용도
TW202432099A (zh) 2022-10-25 2024-08-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406184A (en) * 1966-05-04 1968-10-15 Du Pont Addition compounds of norbornadienes and quadricyclenes with bis(trifluoromethyl) thioketene and their s-oxides and s-dioxides
US3715362A (en) * 1970-08-17 1973-02-06 Lilly Co Eli Tetracyclic aziridine and method for its preparation
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
EP0971878B1 (de) 1997-02-27 2008-03-26 Takeda Pharmaceutical Company Limited Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
CA2404125C (en) * 2000-03-20 2011-01-25 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
ES2248397T3 (es) * 2000-11-02 2006-03-16 MERCK SHARP & DOHME LTD. Sulfamidas como inhibidores de la gamma-secretasa.
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
DE60328182D1 (de) * 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0209991D0 (en) * 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
CA2484159A1 (en) 2003-11-13
AU2003229932B2 (en) 2008-12-11
US20050182109A1 (en) 2005-08-18
CA2484159C (en) 2011-02-22
US7041689B2 (en) 2006-05-09
EP1503998B1 (de) 2009-07-01
AU2003229932A1 (en) 2003-11-17
WO2003093252A1 (en) 2003-11-13
US7282513B2 (en) 2007-10-16
US20060173054A1 (en) 2006-08-03
DE60328182D1 (de) 2009-08-13
US20080070895A1 (en) 2008-03-20
EP1503998A1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
DE60328182D1 (de) Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
ATE444293T1 (de) Cyclische sulfamide zur inhibierung von gamma- sekretase
ATE368031T1 (de) Neue gamma secretase inhibitoren
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
DE60112055D1 (de) Inhibitoren von gamma-secretase
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
NO20070606L (no) Inhibitorer av IAP
JO2646B1 (en) New differentiated cyclic compounds as beta - lactam inhibitors
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
IS7325A (is) alfa-(N-súlfonamíðó)acetamíð afleiður sem beta-amýlóíð tálmar
GB0217757D0 (en) Novel compounds
MA29742B1 (fr) Derives de benzoquinazoline et utilisation de ceux-ci dans le traitement de maladies osseuses
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
DK1483251T3 (da) C3-cyano-epothilon-derivater
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
MX2008002234A (es) Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa.
ATE553077T1 (de) Peptidaseinhibitoren
ATE502631T1 (de) Verbindungen zur behandlung von stoffwechselstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties